The revenue collapse and EPS miss confirm Keros is a pre-revenue clinical-stage biotech with no approved products. The Takeda partnership provides a potential catalyst but no near-term revenue. Monitor for elritercept Phase 3 data and any pipeline updates; the cash runway provides a floor but the stock is likely to trade on binary trial outcomes.
KROS drugs
KROS drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 14 $10.99entry
- T+1 · 6mo ago −4.46%α −3.23% · $10.50
- T+5 · 6mo ago +2.09%α +2.81% · $11.22
- T+20 · 5mo ago −7.64%α −6.79% · $10.15
- T+60 · 3mo ago −2.73%α −6.32% · $10.69
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Keros Therapeutics reported Q1 2026 EPS of -$1.21, a 31.5% miss vs consensus of -$0.92, and revenue of $0.367M, 78.4% below the $1.7M estimate. The net loss of $23.7M compares to net income of $148.5M in Q1 2025, driven by the absence of Takeda license revenue and reduced R&D spend. Cash runway extends into H1 2028, but the revenue collapse and EPS miss signal a pre-commercial biotech with no near-term catalysts beyond Takeda's Phase 3 plans.
Key Financial Metrics
Key Facts
- Q1 2026 EPS of -$1.21 missed consensus of -$0.92 by 31.5%
- Q1 2026 revenue of $0.367M missed consensus of $1.7M by 78.4%
- Net loss of $23.7M vs net income of $148.5M in Q1 2025
- Revenue collapsed 99.8% YoY due to absence of Takeda license revenue
- Cash and equivalents $281.5M, expected runway into H1 2028
- Takeda plans Phase 3 trial for elritercept in myelofibrosis anemia
- Weighted-average shares outstanding fell to 19.6M from 40.6M YoY due to treasury stock
Financial Impact
EPS miss of $0.29 (31.5%) and revenue miss of $1.33M (78.4%) on a $237M market cap
Risk Factors
- No approved products or recurring revenue stream
- Dependence on Takeda partnership for elritercept development
- Clinical trial failure risk for rinvatercept and elritercept
- Dilution risk from potential future equity offerings
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3294851 |
Track record
27 reports on KROS
3 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +12.51% at T+60 after the Jul 30, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 16, 2026today Press Release Neutral 2/10 Entry $10.03 Now $10.03 −0.00% settles Dec 16
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $10.30 Now $10.03 −2.62% settles Dec 14
- Nov 5, 202611d ago 8-K Neutral 3/10 Entry $9.36 Now $10.03 +7.16% settles Dec 7
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $9.36 Now $10.03 +7.16% settles Dec 7
- Nov 5, 202611d ago Press Release Neutral 5/10 No price data
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $11.61 Now $10.03 −13.61% settles Nov 25
- Sep 29, 20266w ago 8-K Bullish 6/10 Entry $11.19 to $11.43 Now $10.03 −10.37% ▲ +2.10% +1.39% vs SPY
- Sep 28, 20267w ago 8-K Neutral 4/10 Entry $11.28 to $11.33 Now $10.03 −11.08% ▲ +0.44% +0.47% vs SPY
- Sep 28, 20267w ago Press Release Neutral 3/10 Entry $11.28 to $11.33 Now $10.03 −11.08% ▲ +0.44% +0.47% vs SPY
- Sep 17, 20268w ago EFFECT Neutral 3/10 Entry $11.36 to $11.10 Now $10.03 −11.71% ▼ −2.29% −3.49% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers